A World Health Organization (WHO) committee said on July 12 that human genome editing technologies to treat serious disease should be shared more generously, to allow poorer nations to benefit from the highly dynamic scientific field.
The IPO train continues to barrel down the tracks as more life sciences companies announced and closed their initial public offerings, bringing millions more to their coffers.
One week after launching a dedicated CRISPR program, Qiagen partnered with San Diego-based Verogen to provide next-generation sequencing human identification workflows to laboratories in order to support forensic efforts from justice departments across the globe.
Intellia Therapeutics and Regeneron Pharmaceuticals shook the biotech and CRISPR world on June 26, announcing positive early data from the first-ever patients to have their DNA edited with an in vivo CRISPR/Cas9 therapy delivered systemically.
In a flurry of activity, multiple biopharma companies made their first appearance on the Nasdaq Stock Exchange on June 25, raising hundreds of millions of dollars to advance the development of next-generation therapeutics and scale their businesses.
Vertex Pharmaceuticals expanded the company’s collaborative partnership with CRISPR Therapeutics to develop and commercialize a possible cure for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The focus is on the development of CTX001, an autologous, ex vivo CRISPR-CAS9 gene-edited therapy.
Caribou Biosciences secured $115 million in an oversubscribed Series C financing round that will be used to advance the company’s pipeline of wholly owned allogeneic immune cell therapies for oncology and its next-generation CRISPR technology platform.
Shares of Cellectis Therapeutics were up in trading after the gene-editing pioneer company forged a deal with Cambridge, Mass.-based Cytovia Therapeutics to develop immunotherapies based on gene-edited allogeneic CAR T-cells.
AbbVie announced the company’s latest chimeric antigen receptor (CAR)-T cell investment, a collaboration with Caribou Biosciences worth $40 million up front in cash and equity to develop two CRISPR-edited cell therapies against AbbVie-specified targets.
At the 2021 virtual JP Morgan Healthcare Conference, Vertex Pharmaceuticals’ chief executive officer Reshma Kewalramani said the company is looking to buy “mid- and late-stage assets.”